Ryan Alexander

Ryan Alexander supports the FDA Center for Drug Evaluation and Research in managing critical procurement initiatives that advance the agency’s mission of ensuring the safety, efficacy, and quality of pharmaceutical products. He oversees acquisitions of scientific, technical, and analytical services essential to drug review processes, including laboratory testing, computational modeling, and biotechnology research support. His work directly enables evidence-based regulatory decisions by securing high-integrity data and infrastructure necessary for evaluating novel therapeutics and generic drug applications. Alexander handles complex, performance-based contracts requiring deep technical oversight and compliance with FDA’s rigorous scientific standards. His primary contractor relationship is with THINKTRENDS, LLC, a vendor frequently engaged to deliver specialized analytical and data management services aligned with the agency’s computational and regulatory science priorities. Alexander fosters long-term, performance-driven partnerships with contractors who demonstrate proven expertise in biopharmaceutical data analysis, bioinformatics, and laboratory validation protocols. His procurement approach emphasizes vendor reliability, technical capability, and adherence to Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) standards. Alexander’s contracting portfolio reflects a balanced approach to socioeconomic goals, with 70% of acquisitions conducted as unrestricted competitions and 30% set aside for total small business participation under FAR 19.5. He consistently prioritizes small business vendors capable of delivering niche scientific and technical services, reinforcing the agency’s commitment to broadening the supplier base while maintaining scientific rigor. His procurement focus centers on NAICS 541380 (testing laboratories), 518210 (data infrastructure and hosting), and 541714 (biotechnology R&D), reflecting his expertise in securing services that support drug evaluation through analytical testing, high-performance computing, and translational research. He routinely procures bioanalytical services, computational toxicology tools, and data integration platforms critical to modern regulatory science.